Characteristics of French methicillin-resistant Staphylococcus aureus isolates with decreased susceptibility or resistance to glycopeptides

According to the French Society of Microbiology, Staphylococcus aureus isolates are suspected to have decreased susceptibility to glycopeptide(s) when at least one colony is able to grow from an inoculum of 10 µL of 2 McFarland bacterial suspension plated on Mueller–Hinton agar containing 5 mg/L tei...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 2003-10, Vol.52 (4), p.691-694
Main Authors: El Solh, Névine, Davi, Marilyne, Morvan, Anne, Damon, Hélène Aubry, Marty, Nicole
Format: Article
Language:English
Subjects:
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
France - epidemiology
Glycopeptides - pharmacology
Humans
Medical sciences
Methicillin Resistance - drug effects
Methicillin Resistance - genetics
Microbial Sensitivity Tests - methods
MRSA
Pharmacology. Drug treatments
Phenotype
S. aureus
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus aureus - growth & development
teicoplanin
vancomycin
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the French Society of Microbiology, Staphylococcus aureus isolates are suspected to have decreased susceptibility to glycopeptide(s) when at least one colony is able to grow from an inoculum of 10 µL of 2 McFarland bacterial suspension plated on Mueller–Hinton agar containing 5 mg/L teicoplanin and incubated for 48 h at 35–37°C. We analysed 89 methicillin-resistant S. aureus isolates (MRSA), collected in 2000–2001 from 24 hospitals located in 18 French cities, which were able to grow on this selective medium. These isolates were distributed into six groups on the basis of their glycopeptide resistance phenotypes: (A) glycopeptide susceptible (GSSA, 21 isolates); (B) heterogeneous teicoplanin intermediately resistant (hetero-TISA, 24 isolates); (C) heterogeneous and intermediately resistant to both glycopeptides, teicoplanin and vancomycin (hetero-GISA, six isolates); (D) heterogeneous vancomycin intermediately resistant/teicoplanin intermediately resistant (hetero-VISA/TISA, 30 isolates); (E) GISA (four isolates); (F) TISA (four isolates). Despite the persistent decrease in gentamicin-resistant MRSA isolates in French hospitals since 1993, their prevalence is very high in groups D, E and F. Moreover, most of the group C, D and E isolates exhibiting decreased susceptibility to both glycopeptides belong to the same major SmaI genotype, which has been detected in Europe since at least 1989.
ISSN:0305-7453
1460-2091
1460-2091
DOI:10.1093/jac/dkg400